📊 MIRM Key Takeaways
Is Mirum Pharmaceuticals, Inc. (MIRM) a Good Investment?
Mirum demonstrates strong revenue growth of 54.7% YoY and improving loss metrics, supported by a solid balance sheet with $324.9M cash and zero debt. However, the company faces severe operational challenges with -$789.5M operating losses, -493.8% operating margin, and unsustainable free cash burn of $229.4M annually, providing only ~1.4 years of runway at current burn rates.
Mirum Pharmaceuticals shows strong fundamental improvement, with revenue up 54.7% year over year and positive operating and free cash flow, which suggests growth is translating into real cash generation. The balance sheet is solid with substantial cash, strong liquidity, and no meaningful leverage, but the company is still slightly unprofitable on a GAAP basis, so the story depends on sustaining growth while converting to durable earnings.
Why Buy Mirum Pharmaceuticals, Inc. Stock? MIRM Key Strengths
- Strong revenue growth of 54.7% year-over-year indicates market demand and sales momentum
- Solid balance sheet with $324.9M in cash, $242.5M stockholders equity, and zero long-term debt provides financial flexibility
- Improving loss trajectory with diluted EPS improving 74.6% YoY suggests operational metrics are moving in the right direction
- Revenue growth is very strong at 54.7% year over year, indicating expanding commercial traction
- Operating cash flow and free cash flow are positive, supporting good growth quality
- Balance sheet strength is high, with $296.68M in cash, a 2.67x current ratio, and effectively no debt
MIRM Stock Risks: Mirum Pharmaceuticals, Inc. Investment Risks
- Massive operating losses of $789.5M with -493.8% operating margin indicate the business model is deeply unprofitable at scale
- Free cash flow burn of $229.4M annually is unsustainable; at current rate provides approximately 1.4 years of cash runway
- No clear timeline to profitability visible; company must dramatically reduce losses or accelerate revenue growth exponentially to sustain operations
- Net income and operating income remain negative, so profitability is not yet fully established
- Margins are still slightly negative, leaving limited room for execution missteps
- As a pharmaceutical company, growth durability can be vulnerable if product expansion or commercialization slows
Key Metrics to Watch
- Operating cash flow trajectory and path to positive cash generation
- Operating margin improvement and timeline to breakeven operations
- Cash burn rate deceleration and monthly burn trend versus revenue growth pace
- Operating margin and net margin progression toward sustained profitability
- Revenue growth relative to operating cash flow and free cash flow conversion
Mirum Pharmaceuticals, Inc. (MIRM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.09x current ratio provides a solid financial cushion.
MIRM Profit Margin, ROE & Profitability Analysis
MIRM vs Healthcare Sector: How Mirum Pharmaceuticals, Inc. Compares
How Mirum Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Mirum Pharmaceuticals, Inc. Stock Overvalued? MIRM Valuation Analysis 2026
Based on fundamental analysis, Mirum Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Mirum Pharmaceuticals, Inc. Balance Sheet: MIRM Debt, Cash & Liquidity
MIRM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Mirum Pharmaceuticals, Inc.'s revenue has grown significantly by 576% over the 5-year period, indicating strong business expansion. The most recent EPS of $-4.00 indicates the company is currently unprofitable.
MIRM Revenue Growth, EPS Growth & YoY Performance
MIRM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $111.6M | -$14.7M | $-0.30 |
| Q3 2025 | $90.4M | $2.9M | $0.05 |
| Q2 2025 | $77.9M | -$5.9M | $-0.12 |
| Q1 2025 | $69.2M | -$14.7M | $-0.30 |
| Q3 2024 | $47.7M | -$14.2M | $-0.30 |
| Q2 2024 | $37.5M | -$24.6M | $-0.52 |
| Q1 2024 | $31.6M | -$25.3M | $-0.54 |
| Q3 2023 | $18.8M | -$23.6M | $-0.57 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Mirum Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
MIRM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Mirum Pharmaceuticals, Inc. (CIK: 0001759425)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MIRM
What is the AI rating for MIRM?
Mirum Pharmaceuticals, Inc. (MIRM) has a Combined AI Rating of HOLD from Claude (SELL) and ChatGPT (BUY) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MIRM's key strengths?
Claude: Strong revenue growth of 54.7% year-over-year indicates market demand and sales momentum. Solid balance sheet with $324.9M in cash, $242.5M stockholders equity, and zero long-term debt provides financial flexibility. ChatGPT: Revenue growth is very strong at 54.7% year over year, indicating expanding commercial traction. Operating cash flow and free cash flow are positive, supporting good growth quality.
What are the risks of investing in MIRM?
Claude: Massive operating losses of $789.5M with -493.8% operating margin indicate the business model is deeply unprofitable at scale. Free cash flow burn of $229.4M annually is unsustainable; at current rate provides approximately 1.4 years of cash runway. ChatGPT: Net income and operating income remain negative, so profitability is not yet fully established. Margins are still slightly negative, leaving limited room for execution missteps.
What is MIRM's revenue and growth?
Mirum Pharmaceuticals, Inc. reported revenue of $159.9M.
Does MIRM pay dividends?
Mirum Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find MIRM SEC filings?
Official SEC filings for Mirum Pharmaceuticals, Inc. (CIK: 0001759425) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MIRM's EPS?
Mirum Pharmaceuticals, Inc. has a diluted EPS of $-13.43.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MIRM a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Mirum Pharmaceuticals, Inc. has a HOLD rating with 76% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MIRM stock overvalued or undervalued?
Valuation metrics for MIRM: ROE of -325.8% (sector avg: 15%), net margin of -494.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MIRM stock in 2026?
Our dual AI analysis gives Mirum Pharmaceuticals, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MIRM's free cash flow?
Mirum Pharmaceuticals, Inc.'s operating cash flow is $-228.8M, with capital expenditures of $664.0K. FCF margin is -143.5%.
How does MIRM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -494.2% (avg: 12%), ROE -325.8% (avg: 15%), current ratio 2.09 (avg: 2).